Phase II Study of Dual Targeting of BCR-ABL1 by adding the Allosteric Inhibitor ABL001 in Patients with Chronic Myeloid Leukemia (CML) and Minimal Residual Disease (MRD) While on Therapy with Tyrosine Kinase Inhibitors
MD Anderson Study Status
This phase II trial studies how well ABL001 works in treating patients with chronic myeloid leukemia who are on therapy with tyrosine kinase inhibitor. ABL001 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving ABL001 and tyrosine kinase inhibitor together may work better than tyrosine kinase inhibitor alone in treating patients with chronic myeloid leukemia.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.